

This form is to be completed by Principal Investigator and submitted to the HKU-GHK IRB Secretary. The HKU-GHK IRB will notify the Principal Investigator about the approval outcome within 4-8 weeks, depending on the complexity of the study. Research activity cannot begin until the protocol has been approved by the HKU-GHK IRB.

1. Research Study Detail	S			
Research Study Title				
HKU-GHK IRB Approval Date (DD-MM-YYYY)			
Study Start Date		Study End Date		
Ciaay Ciair Date		Juan Juli		
2. Principal Investigator	/DI\			
Name	(FI)	Position		
Ivaille		Position		
Department/ Unit/ Ward		Institution/ Hospital		
Department/Only Ward		institution/ Hospital		
Contact Number		Email		
Contact Number		Liliali		
Qualifications & Relevant Eyne	rience (Please add in your short	CV if there is not enough space)		
Qualifications & Relevant Expe	nence (r lease add in your short	ev il there is not enough space)		
For Student PI				
University		Program (Year)		
		1 109:4 (104.)		
Name of Cuparticar		Supervisor Email		
Name of Supervisor		Supervisor Email		
3. Co-Investigators (Plea	se provide short CV)			
Name	Position	Institution & Department	Email	

GQSR-A07-R3-02/20 Page 1 of 8



	Background & Current Evidence (Limit to 300 words)
5.	Aim of Study
	<u>-</u>
I	
	Hypothesis, if any
6.	
6.	

GQSR-A07-R3-02/20 Page 2 of 8



8. Study Participants Inclusion Criteria
Inclusion Criteria
Exclusion Criteria
Exercise Charles
How will participant be recruited?
Sample Size and Calculation
9. Study Design & Methodology
Study Design
and a second
Method in obtaining the data required
Who will perform the date callegation?
Who will perform the data collection?
Where will the data collection take place?
where will the data collection take place?
Study Start and End Dates (DD-MM-YYYY)
Stady Start and End Batos (BB Willi 1111)
10. Methods of Analysis
······································
44 Anticipated Panalita to Participants
11. Anticipated Benefits to Participants

GQSR-A07-R3-02/20 Page 3 of 8



12. Potential Risk Will the study procedures impose side effects to participants? No Perform invasive procedure Induce discomfort or stress Increase physical or psychological risk Involve a potential toxin П Incur other hazards Involve radiation or radioactive substance If yes, please provide details: If yes, measures to minimize risk: Will the study involve the following vulnerable participants? No П Fetuses in uteri/ non-viable fetuses/ abortus Infants (age 0 to <1) Children (age 1 to <13) $\overline{\Box}$ Adolescents (age 13 to <18) Pregnant/ Lactating women Unequal relationship with investigator (e.g. employee, student) Special population (e.g. mentally disabled, prisoner) Other than the above, please specify: If yes, any precautions to protect the interest of the vulnerable participants? 13. Information & Consent Will consent be obtained? Oral Written ▶Go to Section 14 Who will explain the study and collect the consent? Principal Investigator Research Assistant Co-investigators Others, specify: Will an interpreter be available when required? Yes No If participants are incompetent in giving consent, to who will the study be explained? Do participants have a right to withdraw from the study at any time without any penalty or any consequences of any kind? Yes No 14. Medical Product Will any medical product be administered to participants? No -Go to Section 15 Drugs Chinese or Herbal medicines Medical Device Appliance, Diagnostic test Others, specify:

GQSR-A07-R3-02/20 Page 4 of 8



	study sponsored by the industry/ commercial agency?		Yes □ No			
If yes, specify nature of sponsorship:						
1 4						
	product licensed in Hong Kong?	al certif	└│ No icate has been obtained?			
,	orano no regulato, forante e rorocció ante inventor a emilia					
	Confidentiality & Data Protection e study involve:					
	Complete anonymity of participants?					
	Anonymized data?					
	De-identified data?					
	Pseudonymous participant in publication?					
	Other method(s) of protecting the privacy of participar	its? <i>Ple</i>	ease specify:			
How w	vill the data be handled and stored during and after com	pletion	of the study?			
	Data to be kept in a locked cabinet					
	Data and identifiers to be kept in separate and locked Computer files to be accessed by password	Tiling Ca	abinet			
	Electronic data to be encrypted					
	Storage at GHK					
	Store at other study site, portable storage (e.g. Laptor	o, flash	drive) specify:			
Who w	vill have access to the data? Principal Investigator		Research Assistant			
	Co-investigators		Others, specify:			
	· ·		. ,			
How Id	ong will the data be kept and what will be done with ther	n after	completing of storage period?			
	F . P 0 B					
	Funding & Resources e of Funding					

GQSR-A07-R3-02/20 Page 5 of 8



☐ Will this study provide benefit to the investigators or host institution? ☐ Yes ☐ No
If yes, provide details:
Will the study use GHK resources? ☐ Yes ☐ No
If yes, provide details:
17. Expenses & Payments to Participants
Will there be any financial cost to the participant? ☐ Yes ☐ No
If yes, provide details:
Will participants receive any payment from the study? ☐ Yes ☐ No
If yes, provide details:
18. Indemnity
Will there be any indemnity?
If yes, provide details:
Is the indemnity supported by an insurance policy
If yes, please provide an insurance certificate for review
19. Publication & Dissemination of Research Results Will the results of the research be reported and disseminated? □ Yes □ No
Will the results of the research be reported and disseminated? Yes No If yes, provide details:
, 9-5, p. 5-1
20. Other Ethical Issues
20. Other Ethical Issues Are there any other ethical issues that have not been addressed? ☐ Yes ☐ No
If yes, provide details:

GQSR-A07-R3-02/20 Page 6 of 8



21. Declarations by Investigators

A. B. C. D. E. H.	 I/We have attempted to identify all risks related to the research that may arise in conducting this research and acknowledge my obligations and the rights of the participants. I/We shall comply with the principles enunciated in the 2017 or a later version of the Research Policy of Gleneagles Hong Kong Hospital. I/We agree to report study progress to HKU-GHK IRB as requested, and to submit a final report at the end of the research project. I/We agree to report to HKU-GHK IRB any planned change in the study, and do not implement any change without receiving prior approval, except to eliminate immediate hazard to participants or when the change involves only logistical or administrative issues. I/We agree to report to HKU-GHK IRB any unanticipated problems involving risks to participants such as a severe adverse event within 24 hours of its identification. I/We shall report potential conflict of interest to the HKU-GHK IRB that may arise in the course of the approved study. I/We agree to ensure that all associates, colleagues, and employees assisting in the conduct of the study are informed about their obligations in meeting the above commitments. I/We declare that I have no conflict of interest. 						
		P	Principal Investigat	tor			
		Title & Name		Signature	Date		
			Co-investigators				
			oo miyoongatoro				
			· · · · / · · · · · · · · · · · · · · ·	. ()			
		Super	rvisor (For student	project)			
					1		
		COS or Department Heads		undertaken in mu denertare	nt upon approval by		
A.	the HKU-GHK IRE		ted the study to be	undertaken in my departme	п ироп арргочаг бу		
B.	I confirm that the i	nvestigator(s) are appropriat		research area involved to con			
		and the study site(s) under m nducted in a safe manner.	ny supervision have	access to adequate facilities	s and support for the		
C.	I support the study	y and verify that the workload	d to be incurred will	not interfere with the departr	ment's service priority.		
	Nome	Cianatura	Doot Do	rtmont Mord/Contro	Doto		
	Name	Signature	Post, Depa	rtment, Ward/Centre	Date		

GQSR-A07-R3-02/20 Page 7 of 8



FOR HKU-GHK IRB Office Use

Application Log						
Submission		Initial Submission		☐ Re-submission ()	
Application Reference Number	HKI	U-GHK IRB				
Date of Application Received Acknowledgement Receipt to Applicant Submit to HKU-GHK IRB Members					DD-MM DD-MM	I-YYYY
Type if Review		Full Panel Review Approved		☐ Expedited Review ☐ Conditionally Approved		
Approval Outcome		Approval Deferred		☐ Not Approved		
Notify Applicant of Approval Outcome					DD-MM	I-YYYY
Documents Enclosed					Yes	No
Research Protocol						
Ethical Clearance Checklist						
Participant Consent Form	Chinese	•		English		
PI's short CV						
Co-investigators' short CV						
Written Information to Participant (e.g. Information sheet, Invitation letter, recruitment advertisement, etc.)	☐ Invi	rmation Sheet tation Letter cruitment advertisem	ent			
Questionnaires	⊔ Otn	er, specify:			П	П
Investigator's Brochure						
Indemnity Agreement						
Insurance Certificate with Number:			Validity I	Date:		
Other Research Ethics Approval						
Others:						
Study Monitoring						
Study Start date					DD-MN	I-YYYY
Study end date					DD-MM	I-YYYY
Planned first Progress Report date					DD-MM	I-YYYY
Date of SAE					DD-MM	I-YYYY
Date of amendment notification					DD-MM	
Extension approved study period					DD-MM	I-YYYY
Date of termination					DD-MM	I-YYYY

GQSR-A07-R3-02/20 Page 8 of 8